Displaying 2281 - 2300 of 2639
Improving the Economic Foundations of Competition Policy
FTC Competition Director Announces Best Practices for Merger Investigations
Looking Forward: The Federal Trade Commission and the Future Development of U.S. Competition Policy
FTC Releases Health Care and Competition Law and Policy Workshop Materials
Efficiencies and Antitrust: A Story of Ongoing Evolution
Possible Anticompetitive Efforts to Restrict Competition on the Internet
FTC Releases Agenda for Public Workshop on Possible Anticompetitive Efforts to Restrict Competition on the Internet
FTC Testifies on Internet Competition
Workshop on Health Care and Competition Law and Policy
Federal Trade Commission Announces Formation of Merger Litigation Task Force
Libbey, Inc. Settles FTC's Administrative Litigation
MSC.Software Settles FTC Charges by Divesting Nastran Software
Competition Agencies in a Market-Based Global Economy
Physician Integrated Services of Denver, Inc., Michael J. Guese, M.D., and Marcia L. Brauchler
Aurora Associated Primary Care Physicians, L.L.C., Richard A. Patt, M.D., Gary L. Gaede, M.D., and Marcia L. Brauchler
Resolving Anticompetitive Concerns, FTC Clears $16 Billion Acquisition of Immunex Corp. By Amgen Inc.
Biovail Corporation
The Commission charged Biovail Corporation with illegally acquiring an exclusive patent license for Tiazac, a pharmaceutical used to treat high blood pressure and chronic chest pain. The complaint further alleged that Biovail, in an effort to maintain its monopoly, wrongfully listed the acquired license in the U.S. Food and Drug Administration’s “Orange Book” for the purpose of blocking generic competition to its branded Tiazac. The consent order requires Biovail to divest part of its exclusive rights to DOV; prohibits the firm from taking any action that would trigger additional statutory stays on final FDA approval of a generic form of Tiazac; and also prohibits Biovail from wrongfully listing any patents in the Orange Book for a product for which the company already has an New Drug Application from the FDA.
FTC Seeks to Block Cytyc Corp.'s Acquisition of Digene Corp.
Displaying 2281 - 2300 of 2639